Zomedica Stock Price, News & Analysis

Zomedica Corp. (symbol ZOM) is an animal health company focused on equine and companion animal care. According to company disclosures and recent announcements, Zomedica provides veterinarians with therapeutic and diagnostic device products designed for use at the point of care in clinical settings. The company is described as an equine and companion animal healthcare company dedicated to improving animal health by equipping veterinarians with specific tools for diagnosis, monitoring, and treatment.

Business focus and product platforms

Zomedica states that its business centers on point-of-care diagnostic and therapeutic device products for equine and companion animals. Its portfolio includes the PulseVet shock wave system, the Assisi and Assisi Loop line of therapeutic devices, the TRUFORMA in-clinic diagnostic platform, the TRUVIEW digital cytology system, the VETGuardian no-touch (Zero Touch) monitoring system, and the VETIGEL hemostatic gel. Company materials describe PulseVet as a shock wave system used in musculoskeletal conditions, while the Assisi and Calmer Canine product lines use targeted pulsed electromagnetic field (tPEMF) technology for pain, inflammation, and anxiety-related indications in animals.

The TRUFORMA platform is presented as an in-clinic diagnostic system that delivers reference-lab quality results at the point of care. Zomedica has highlighted assays for equine endocrinology, including endogenous ACTH and insulin, and has announced an equine progesterone assay aimed at reproductive health management. The company has also expanded TRUFORMA’s menu with a multiplexed cobalamin and folate assay for canine and feline use, enabling veterinarians to obtain both results in a single in-clinic test.

TRUVIEW is described as a digital cytology microscope and imaging system that automates slide preparation and imaging. Zomedica reports that TRUVIEW uses micro-stream fluid dispensing, automated slide smearing, and integrated imaging to create laboratory-quality blood films and cytology slides in the clinic. The VETGuardian system is characterized as a Zero Touch monitoring platform that captures vital signs such as heart rate, respiration, and body temperature without wires or physical contact, aiming to reduce patient stress and support continuous monitoring.

Therapeutic devices and tPEMF technology

Within its therapeutic segment, Zomedica emphasizes the Assisi Loop and Assisi Loop Lounge products, which are non-invasive devices using targeted pulsed electromagnetic field (tPEMF) technology. Company descriptions state that these devices are used to reduce inflammation, relieve pain, and accelerate healing in animals. The Assisi Loop Lounge is presented as a tPEMF therapy bed that delivers full-body treatment and is used in clinics, hospice and palliative care, and at home for conditions such as osteoarthritis, chronic pain, post-surgical recovery, and mobility support.

The Calmer Canine system is also identified as a tPEMF-based, non-pharmaceutical solution intended for dogs experiencing anxiety and separation stress. Zomedica materials describe these systems as drug-free options used by veterinarians, rehabilitation specialists, and pet parents, with an emphasis on comfort and long-term use.

Diagnostics, monitoring, and hemostatic solutions

In diagnostics, Zomedica highlights TRUFORMA’s role in equine and companion animal testing. The company has announced assays for endocrine conditions and gastrointestinal-related biomarkers such as cobalamin and folate, with an emphasis on delivering results in minutes to support same-visit treatment decisions. The equine progesterone assay is described as a reproductive management tool for breeding programs and pregnancy monitoring, intended to help veterinarians assess progesterone levels at the point of care.

The TRUVIEW digital cytology system is positioned as a way to standardize slide preparation and improve diagnostic confidence by enabling automated, consistent blood films and cytology slides. Zomedica reports that this system addresses challenges related to manual slide preparation and sample degradation. VETGuardian is described as a Zero Touch monitoring solution that uses radar and imaging technology to monitor patients without physical contact, which the company associates with improved animal welfare and workflow efficiency in veterinary practices.

VETIGEL hemostatic gel is identified by Zomedica as a hemostatic agent or gel that rapidly stops bleeding. The company has referenced VETIGEL as part of its therapeutic portfolio and as a product included in distribution agreements for equine and companion animal markets.

Geographic footprint and operations

Zomedica states that it is headquartered in Michigan and that it manufactures and distributes its products from facilities in Georgia and Minnesota. Company communications describe a workforce of approximately 150 people and reference a total addressable market in the United States for its portfolio that the company estimates at more than $2 billion. Zomedica also notes that it is expanding internationally, including through distribution partnerships.

Recent announcements describe an expanded distribution agreement with Grovet b.v., an equine health company based in the Netherlands. Under this agreement, Grovet distributes equine therapeutic devices such as PulseVet systems and the TRUFORMA diagnostic platform across Europe and adds VETIGEL hemostatic gel and EquiLoop therapeutic devices to its portfolio. The agreement also provides for transitional support for Zomedica’s entry into the European companion animal market.

Intellectual property and development services

Zomedica has reported that it holds a substantial intellectual property portfolio related to its TRUFORMA and TRUVIEW platforms. In one announcement, the company states that it has 83 U.S. patents and 145 international patents, along with 37 U.S. and 116 foreign trademarks, and that it continues to pursue additional patent applications. Recent U.S. patents include protections for methods and systems for slide processing in the TRUVIEW microscope and a "Crowded Sensor" technology for acoustic wave sensors used in diagnostics.

In addition to its veterinary-focused products, Zomedica has described a Development Services business segment. This segment captures revenue from development and engineering services, contract manufacturing, and licensing of intellectual property for a company in the human health space. The company presents this segment as a way to leverage existing infrastructure and intellectual property assets.

Market positioning and segments

Company communications divide Zomedica’s revenue into diagnostics, therapeutic devices, consumables, capital equipment, and engineering services. The diagnostics segment includes TRUFORMA, TRUVIEW, and VETGuardian products. The therapeutic device segment includes PulseVet and Assisi products. Consumables include items such as PulseVet trodes and diagnostic assays associated with installed platforms. Capital revenues are associated with sales of systems such as PulseVet and VETGuardian, while engineering services revenues are associated with the Development Services segment.

Zomedica characterizes its target markets as equine and companion animal veterinarians, breeders, and related veterinary professionals. The company highlights demand for point-of-care diagnostics, non-pharmaceutical pain management, and advanced monitoring solutions as drivers for adoption of its platforms. It also references global and regional market estimates for veterinary diagnostics, equine healthcare, equine reproductive technologies, and veterinary monitoring when discussing the context for its product and distribution strategies.

Communications and investor outreach

Zomedica engages with veterinarians, investors, and other stakeholders through recurring webinar series branded as "Fourth Friday at Four" and similar events. These webinars have featured overviews of the company’s strategy, financial performance, and detailed sessions on specific products such as the TRUVIEW digital cytology microscope and the VETGuardian Zero Touch monitor. The company also issues regular press releases regarding product launches, assay expansions, distribution agreements, and financial results.

FAQs about Zomedica

• What does Zomedica do?
  Zomedica is an animal health company that offers point-of-care diagnostic and therapeutic device products for equine and companion animals. Its portfolio includes systems for shock wave therapy, tPEMF-based therapeutic devices, in-clinic diagnostics, digital cytology, no-touch monitoring, and hemostatic gel products.
• Which animals are the focus of Zomedica’s products?
  Company materials consistently describe a focus on equine and companion animals. Companion animals referenced include canine and feline patients, and Zomedica also notes use of certain therapeutic products for other small animals.
• What are Zomedica’s main diagnostic platforms?
  Zomedica’s main diagnostic platforms are TRUFORMA, an in-clinic diagnostic system with assays for endocrine and gastrointestinal markers, and TRUVIEW, a digital cytology microscope that automates slide preparation and imaging. The VETGuardian system adds no-touch patient monitoring capabilities.
• What therapeutic technologies does Zomedica highlight?
  The company highlights the PulseVet shock wave system for musculoskeletal conditions and the Assisi and Assisi Loop products, including the Assisi Loop Lounge, which use targeted pulsed electromagnetic field technology. It also references the Calmer Canine system for anxiety and VETIGEL hemostatic gel for rapid control of bleeding.
• Where is Zomedica headquartered?
  Zomedica states that it is headquartered in Michigan and that it manufactures and distributes its products from facilities in Georgia and Minnesota.
• How does Zomedica reach international markets?
  Zomedica reports that it is expanding internationally through distribution partners. An example is its expanded agreement with Grovet b.v. in the Netherlands, which distributes equine therapeutic devices and diagnostic platforms across parts of Europe and supports Zomedica’s entry into the European companion animal market.
• What is the Development Services segment?
  The Development Services segment is described as a business area where Zomedica provides development and engineering services, contract manufacturing, and licensing of its intellectual property, including work for a company in the human health sector.
• How important is intellectual property to Zomedica?
  Zomedica emphasizes that it holds numerous U.S. and international patents and trademarks covering its TRUFORMA and TRUVIEW platforms and related technologies. The company presents this intellectual property portfolio as a way to protect its products and support its position in veterinary diagnostics.
• Is Zomedica still an active public company?
  Recent press releases and an 8-K filing reporting quarterly financial results indicate that Zomedica continues to operate and report financial performance as a public company.
• What markets does Zomedica identify for its products?
  In its communications, Zomedica references multi-billion-dollar markets for veterinary diagnostics, equine healthcare, equine reproductive technologies, veterinary monitoring, and animal-health tPEMF and electrotherapy, and notes that the total addressable market in the U.S. for its own portfolio exceeds $2 billion by its estimates.